Novartis files ceritinib as data show selectivity bonus
This article was originally published in Scrip
Clinical data supporting a US approval application for Novartis's novel ALK inhibitor ceritinib (LDK378) suggest that it is effective in most patients who become resistant to Pfizer's first-in-class product Xalkori (crizotinib), with a reassuring safety profile.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.